< Back to search
Filter
1

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

for
Lymphocytic Leukemia, Chronic, SLL
Location: Boston MA, Durham NC
Sponsor: Catapult Therapeutics

Sex: All

Age: 18+

Code: NCT04704323

Phase1, Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT05336812

Phase2, Recruiting

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

for
Non-Hodgkin's Lymphoma, Hodgkin's Disease,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT00131014

Recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma,
Location: Columbus OH, Sioux Falls SD, Orange CA, Eugene OR
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT01804686

Phase3, Recruiting

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

for
Chronic Lymphocytic Leukemia
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: All

Age: 18+

Code: NCT04785989

Recruiting

Interested in new leukemia, lymphocytic, chronic, b-cell trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT04560322

Phase2, Recruiting

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

for
Chronic Lymphocytic Leukemia (CLL),
Location: Scarborough ME, South Weymouth MA, Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT05168930

Phase2, Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

for
Chronic Lymphocytic Leukemia (CLL),
Location: New Haven CT, Philadelphia PA, Bethesda MD, Durham NC,
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05131022

Phase1, Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

for
Chronic Lymphocytic Leukemia,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 0+

Code: NCT06151730

Recruiting

Understanding Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04028531

Recruiting

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

for
Chronic Lymphocytic Leukemia, Richter's Transformation
Location: Boston MA, Chapel Hill NC, Columbus OH, Atlanta GA
Sponsor: Christine Ryan

Sex: All

Age: 18+

Code: NCT06043674

Phase2, Recruiting

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

for
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT03501576

Recruiting

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Location: Columbus OH
Sponsor: Seema Bhat

Sex: All

Age: 18+

Code: NCT06757647

Phase2, Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

for
Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
Location: Boston MA, Tampa FL, Fort Wayne IN, St Louis MO,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06697184

Phase1, Phase2, Recruiting

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

for
Chronic Lymphocytic Leukemia (CLL),
Location: Boston MA, Durham NC, Winston-Salem NC, Charlotte NC
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT07024706

Phase2, Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Location: New York NY, Jacksonville FL, Mobile AL, Coon Rapids MN
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07218341

Recruiting

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

for
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma,
Location: Fort Wayne IN
Sponsor: Grifols Biologicals, LLC

Sex: All

Age: 18+

Code: NCT07582432

Phase3, Recruiting

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

for
CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory,
Location: Bethesda MD, Skokie IL, Spokane WA, Las Vegas NV
Sponsor: Newave Pharmaceutical Inc

Sex: All

Age: 18+

Code: NCT07342478

Phase3, Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia
Location: Boston MA, Quebec, Sherbrooke, New York NY, Montreal,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07277231

Phase3, Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

for
Chronic Lymphocytic Leukemia (CLL),
Location: Norfolk VA, Silver Spring MD, Fairfax VA, Durham NC,
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07221500

Phase2, Recruiting